用于降低肥胖症患者心血管代谢风险的胰高血糖素样肽-1受体激动剂——我们如何最好地描述其益处和价值？

GLP-1 RA for cardiometabolic risk reduction in obesity - How do we best describe benefit and value?

作者信息

Kumar Sant, Blaha Michael J

机构信息

MedStar Georgetown University Hospital, Washington, D.C. 20007, United States.

Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD 21287, United States.

出版信息

Am J Prev Cardiol. 2024 May 18;18:100682. doi: 10.1016/j.ajpc.2024.100682. eCollection 2024 Jun.

DOI:10.1016/j.ajpc.2024.100682

PMID:38840935

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11152602/

Abstract

How do we assess the overall benefit and value of GLP1-RAs? Current clinical trials often focus narrowly on individual atherosclerotic cardiovascular endpoints like MACE, potentially missing broader GLP-1 RA benefits across multiple comorbidities. Herein, we set out a framework for expanding outcome analyses in large trials that we believe will provide a more holistic understanding of GLP-1 RA benefits across the cardio-kidney-metabolic (CKM) spectrum, guiding patient care, guidelines, and insurance coverage decisions.

摘要

我们如何评估胰高血糖素样肽-1受体激动剂（GLP1-RAs）的总体益处和价值？当前的临床试验往往狭隘地聚焦于个别动脉粥样硬化性心血管终点，如主要不良心血管事件（MACE），可能会遗漏GLP-1 RA在多种合并症方面更广泛的益处。在此，我们提出了一个在大型试验中扩展结局分析的框架，我们认为这将提供对GLP-1 RA在心脏-肾脏-代谢（CKM）范围内益处的更全面理解，从而指导患者护理、指南制定以及保险覆盖范围决策。